System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Sven Francque is an expert in Hepatology at Antwerp University Hospital (Belgium). As of October 2026, ScienceLeadR ranks Sven Francque in the top 1% of experts worldwide for Alcohol-Induced Disorders, MASH and Liver Cirrhosis. Sven Francque has authored 496 publications, the most recent in 2026, and is an investigator in 113 clinical trials, 10 of them ongoing. SLR score: 3,354 (community average: 125). How the SLR is computed.

LeadR Profile

Sven Francque Antwerp University Hospital Belgium
3 354 ScienceLeadR Reputation 3354

Unlock

Register Login
Network Map

Hepatology

Subspecialties: Gastroenterology - Endocrinology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2002 - 2026
Source: PubMed

Antwerp University Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 496

Citations

Citations: 31 756 1st author: 44 Last author: 74 Unique author: 10

Main journals

J Hepatol 145
Hepatology 27
Acta Gastroenterol Belg 23
JHEP Rep 19
Gastroenterology 16

Best Journals

J Hepatol 40
Lancet Gastroenterol Hepatol 7
N Engl J Med 7

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Gender differences in stigma and care avoidance among people living with MASLD: an international survey.
PMID 42686023 — liver diseases, non-alcoholic fatty liver disease, liver, retention in care, sex characteristics, sex differences		JHEP Rep20260
Elafibranor in primary biliary cholangitis: two-year placebo-controlled outcomes and long-term open-label data from the ELATIVE® phase III trial.
PMID 42660235 — liver diseases, cholangitis, safety, liver, pruritus, fatigue, therapeutics		J Hepatol Top journal20260
Steatotic liver disease trajectory: A holistic EASL guidance on the multidisciplinary approach to screening and patient management.
PMID 42617506 — liver diseases, multiple chronic conditions, liver		JHEP Rep20263
Non-invasive Assessment and Therapeutic Targeting in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Overcoming the Dissonance Between Drug Development and Precision Medicine.
PMID 42625107 — liver diseases, drug development, fibrosis, pharmaceutical preparations, non-alcoholic fatty liver disease, biopsy, drug therapy, liver, biomarkers, precision medicine, diagnosis, therapeutics		Drugs20260
Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma: Summary of the First Annual Paris International Liver Meeting 2026.
PMID 42613687 — liver diseases, hypertension, carcinoma, hepatocellular, cholangitis, fibrosis, non-alcoholic fatty liver disease, liver, hypertension, portal, therapeutics, hepatitis, peroxisome proliferator-activated receptors		Liver Int20260

Clinical Studies 113

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 7

By phase:

Phase 3 50
Phase 2 35
N/A 17
Phase 1/Phase 2 5
Phase 4 4
Phase 1 2

By status:

Completed 72
Terminated 16
Recruiting 10
Active not recruiting 7
Unknown 5
Suspended 2
Not yet recruiting 1

By type:

Interventional 99
Observational 14

By Monocentric/Multicentric:

monocentric 20
multicentric2to4 3
multicentric5to9 4
multicentricup10 86

Main Topics

Cohort/Consortium Investigators 3

Ongoing Clinical Trials

10 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction Associated Steatotic Liver Disease (SYNERGY Outcomes)
2025-522674-36-00 — liver diseases, liver		Phase 3Recruiting2026
Study to learn about the safety of fazirsiran and if it can help people with alpha 1 antitrypsin liver disease with mild liver scarring (fibrosis)
2023-504198-19-00 — liver diseases, safety, fibrosis, alpha 1-antitrypsin deficiency, liver, therapeutics, alpha 1-antitrypsin		Phase 3Not yet recruiting2024
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction Associated Steatotic Liver Disease (SYNERGY Outcomes)
NCT07165028 — liver diseases, non-alcoholic fatty liver disease, liver, alcoholics, incretins, fatty liver, fatty liver, alcoholic		Phase 3Recruiting2025
Referral of Patients to Hepatology With Hepatoscope
NCT06387745 — liver diseases, research design, fibrosis, elasticity imaging techniques, ultrasonography, liver, tissues, pulse		N/ARecruiting2025
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha 1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
NCT06165341 — liver diseases, injections, safety, fibrosis, alpha 1-antitrypsin deficiency, liver, therapeutics, alpha 1-antitrypsin		Phase 3Recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS